— Know what they know.
Not Investment Advice
Also trades as: BCT.TO (TSX) · $vol 0M · BCTXL (NASDAQ) · $vol 0M · BCTXW (NASDAQ) · $vol 0M

BCTX NASDAQ

BriaCell Therapeutics Corp.
1W: -6.5% 1M: +13.2% 3M: +15.4% YTD: -43.6% 1Y: -67.9% 3Y: -99.6% 5Y: -99.1%
$4.04
-0.07 (-1.70%)
 
Weekly Expected Move ±10.9%
$3 $4 $4 $4 $5
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 58 · $35.1M mcap · 8M float · 3.34% daily turnover · Short 53% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$35.1M
52W Range2.6-14.68
Volume104,917
Avg Volume262,420
Beta1.52
Dividend—
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOWilliam V. Williams
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2012-03-14
Bellevue Centre
West Vancouver, BC V7T 2X1
CA
604 921 1810
About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

Recent Insider Trades

NameTypeSharesPriceDate
Bondarenko Jamieson 0 — 2022-08-01
Lustig Marc 0 — 2022-08-01
Schmieg Martin E. 0 — 2022-08-01
Embro-Pantalony Vaug 0 — 2022-08-01
Williams Williams V. 0 — 2022-08-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms